daaimon

daaimon is an independent research company focusing on healthcare and consumer sectors across developed and emerging markets. We produce insightful research which challenges conventional thinking. In particular, we look for new ideas by testing consensus forecasts and markets expectations.

Innovent Biologics(1801 HK)– More than Just a GLP-1 Play

Understanding Drug Imbursement Price Cuts in China

Healthcare Equity Analyst - Emerging & Dev Markets, daaimon

Avien Pillay

Healthcare Equity Analyst - Emerging & Dev Markets

Independent Insight Provider

Equity Bottom-Up

Innovent Biologics Inc / Equity Bottom-Up

<ul>
<li>Strong results reflect progress of existing approved drugs including key oncology drugs.</li>
<li>Mazdutide is set to be released in 2025, and the company is currently making plans for the release.</li>
<li>Innovent Biologics continues to add to its drug development portfolio.</li>
</ul>


Strong results reflect progress of existing approved drugs including key oncology drugs.
Mazdutide is set to be released in 2025, and the company is currently making plans for the release.
Innovent Biologics continues to add to its drug development portfolio.


Innovent Biologics Inc

Update on Innovent Biologics (1801 HK)